Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Curcumin Bioavailability in Glioblastoma Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Stephan Dützmann, Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier:
NCT01712542
First received: October 20, 2012
Last updated: June 1, 2013
Last verified: June 2013
  Purpose

Measuring the bioavailability of orally administered curcumin in the tumors of glioblastoma patients.


Condition Phase
Patient Harboring Glioblastoma That Will Undergo Surgery
Phase 0

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement of Intratumoral Concentration of the Nontoxic Natural Compound Curcumin in Glioblastoma Patients

Resource links provided by NLM:


Further study details as provided by Johann Wolfgang Goethe University Hospitals:

Primary Outcome Measures:
  • Concentration of Curcumin in Glioblastoma [ Time Frame: At Tumor resection ] [ Designated as safety issue: No ]
    At the time of surgery


Biospecimen Retention:   Samples Without DNA

Tumor tissue


Estimated Enrollment: 15
Study Start Date: October 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients harboring Glioblastoma

Criteria

Inclusion Criteria:

  • Patients harboring Glioblastoma
  • Patient will undergo surgery

Exclusion Criteria:

  • BMI > 30
  • Liver and Kidney Function so compromised that medication is prescribed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01712542

Locations
Germany
Department of Neurosurgery, Johann Wolfgang Goethe-University
Frankfurt, Hessen, Germany, 60528
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospitals
Investigators
Principal Investigator: Stephan Duetzmann Goethe University
  More Information

Additional Information:
Publications:
Responsible Party: Stephan Dützmann, M.D., Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier: NCT01712542     History of Changes
Other Study ID Numbers: JohannWGUH_Curcumin-01
Study First Received: October 20, 2012
Last Updated: June 1, 2013
Health Authority: Regierungspräsidium Darmstadt: Germany

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors

ClinicalTrials.gov processed this record on November 20, 2014